Sapience Therapeutics to Present at RBC Capital Markets Private Healthcare Company Conference | New


HARRISSON, NY, December 1, 2021 / PRNewswire / – Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapies to treat difficult-to-treat cancers, today announced that the company will make a presentation at the RBC Capital Markets conference Healthcare Private Company, place virtually on December 15-16, 2021.

Dr. Barry kappel, CEO and President, will participate in a fireside chat on December 16, 2021 To 2:30 p.m. ET. In addition, company management will participate in one-on-one meetings with life science investors during the event.

About Sapience Therapeutics

Sapience Therapeutics, Inc. is a privately-held, clinical-stage biotechnology company focused on the discovery and development of peptide-based therapies for major unmet medical needs, particularly high mortality cancers. Through the on-platform discovery of peptide therapies that disrupt protein-protein interactions, Sapience molecules have the potential to target intracellular interactions that are traditionally considered “non-drug targets”. Its lead compound, ST101, is a first-class molecule with potential applications in various solid tumors and hematologic malignancies. For more information on Sapience Therapeutics, please visit and contact us on LinkedIn.

Caution regarding forward-looking statements

This press release contains forward-looking statements. Any statement in this document other than statements of historical fact could be considered as forward-looking statements. These forward-looking statements may include, among others, statements regarding future events that involve significant risks and uncertainties (including with respect to Sapience’s preclinical and clinical development programs). These forward-looking statements are based on management’s current expectations, and actual results and future events may differ materially due to certain factors, including, without limitation, risks associated with the application of the net proceeds of offering to Sapience’s product development objectives, our ability to raise additional funds, meet applicable regulatory standards and receive required regulatory approvals. Forward-looking statements speak only as of the date of this press release. Sapience assumes no obligation to update forward-looking statements as a result of new information, future events, changed assumptions or otherwise, except as required by law.


Sapience Therapeutics, Inc.

Barry kappel, Ph.D., MBA

President and CEO

Media and investor contact:

Amy conrad

Juniper hint

(858) 366-3243

View original content to download multimedia: .html

SOURCE Sapience Therapeutics, Inc.

Source link


Comments are closed.